34.47
+0.46(+1.35%)
Currency In USD
| Previous Close | 34.01 |
| Open | 34 |
| Day High | 34.57 |
| Day Low | 33.95 |
| 52-Week High | 62.58 |
| 52-Week Low | 23.41 |
| Volume | 41,518 |
| Average Volume | 903,593 |
| Market Cap | 1.97B |
| PE | 2.96 |
| EPS | 11.66 |
| Moving Average 50 Days | 41.5 |
| Moving Average 200 Days | 42.74 |
| Change | 0.46 |
If you invested $1000 in Agios Pharmaceuticals, Inc. (AGIO) 10 years ago, it would be worth $304.77 as of February 05, 2025 at a share price of $34.47. Whereas If you bought $1000 worth of Agios Pharmaceuticals, Inc. (AGIO) shares 5 years ago, it would be worth $694.82 as of February 05, 2025 at a share price of $34.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
– FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date is September 7, 2025 – – Topline Results from Pha
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
GlobeNewswire Inc.
Jan 03, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to prese